Using data from CDC’s National Healthcare Safety Network (NHSN), the 2018 HAI Progress Report shows the following reductions have been achieved nationally among acute care hospitals (2017 – 2018):
About 9% decrease in central line-associated bloodstream infections (CLABSIs)
About 8% decrease in catheter-associated urinary tract infections (CAUTIs)
No significant changes in ventilator-associated events (VAEs)
No significant changes in surgical site infections (SSIs) related to the 10 procedures tracked in the report
No significant changes in hospital-onset methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections
About 12% decrease in hospital-onset C. difficile infections
Each day, approximately one in 31 U.S. patients have at least one infection in association with his or her hospital care, underscoring the need for improvements in patient care practices in U.S. healthcare facilities. While much progress has been made, more needs to be done to prevent healthcare-associated infections in a variety of settings. Ongoing collaboration between public health, healthcare professionals, and other partners is critical to ensuring patient safety.
Additionally, the HAI Progress Report data are now available in CDC’s newAntibiotic Resistance & Patient Safety Portal (AR&PSP), an interactive web-based application that was created to innovatively display data collected through CDC’s NHSN and other sources. We hope you’ll use the AR&PSP to view enhanced data visualizations on Antibiotic Resistance, Use, and Stewardship datasets as well as HAI data for the nation and states.
Drug-resistant infections have been a growing concern across the medical and pharmaceutical industries. In the United States alone, approximately 23,000 people die each year from infections that are resistant to antibiotics. Now, researchers may know why this happens.
New findings from researchers at Imperial College London show that these bacterial infections are able to reject antibiotics by “closing tiny doors in their cell walls.”
By understanding how these cells are able to shut the doors, the researchers said this could provide new understandings for drugmakers to develop treatments that will “pick the locks” of the closed doors. The result of the research was published today in Nature Communications In the study, the Imperial College researchers, who are focused on antibiotic resistance, looked at the bacterium Klebsiella pneumoniae, which causes infections in the lungs, blood and wounds of people in hospitals. Patients that have compromised immune systems are especially vulnerable to this bacterium. The researchers said K. pneumoniae is becoming increasingly resistant to antibiotics, particularly a family of drugs called Carbapenems, which are used in hospitals when others have failed or are ineffective. Because of this resistance to the powerful antibiotics, the World Health Organization listed Carbapenem-resistant K. pneumoniae as a critical problem.
The researchers found that K. pneumoniae is able to resist Carbapenems by shutting down it surface pores, which is how the antibiotics typically attack the bacteria. The team compared the structures of K. pneumoniae bacteria that were resistant to Carbapenems to those that weren’t and found the resistant bacteria had modified or absent versions of a protein that creates pores in the cell wall. Resistant bacteria have much smaller pores, blocking the drug from entering, the researchers said in a statement. Joshua Wong, from the Department of Life Sciences at Imperial and first author of the study, said with the growing threat of antibiotic-resistant bugs like K. pneumoniae, it’s important to understand how it happened in order to provide “vital insights that could allow new strategies and drugs to be designed.”
There is some good news though from this finding. The researchers said that the bacteria grow at a much slower rate when its doors are closed due to its inability to absorb nutrients while being attacked by the antibiotics.
Those closed doors will present a challenge to drug developers. Gad Frankel, head of the study team, said the ability of the bacteria to shut its doors to the antibiotics will also provide a mechanism to counteract many other drugs. He said that ability will be difficult to get around.
“However, we hope that it will be possible to design drugs that can pick the lock of the door, and our data provide information to help scientists and pharmaceutical companies make these new agents a reality,” Frankel said in a statement.
Over the past few years, there have been multiple stories about the rise of drug-resistant pathogens. Recently, a dangerous fungal infection known as Candida auris reared its head in a New York hospital. The facility had to tear out part of the room a patient was housed in due to the spread of the fungal infection, which can be fatal. With growing concerns about the rise of drug-resistant bacteria, multiple companies are developing new forms of antimicrobials to take on serious health concerns, such as carbapenem-resistant enterobacteriaceae, Clostridium difficile, better known as C. diff, or Staphylococcus infections
to review article in its entirety please click on the following link to be redirected:
With its fresh Spring mornings and lovely long evenings – not to mention an extra long weekend – it’s no wonder that May is the official National Walking Month. Whether you prefer leisurely strolls or challenging hikes, our four park surroundings have a walk for everyone to raise awareness of C.diff., walk for a cause in all locations. Lace up your walking shoes and venture out to Milton A. Votee Park, Teaneck, N.J., Charlestown Township Park, Phoenixville, PA.,Sims Park, New Port Richey, FL., on Saturday, May 18th to experience one of these 3 C.diff. Awareness 2k walks.
The USA events will take place on Saturday, May 18, 2019 from 8 a.m. – 12 p.m.
Dr. Martha Cloakie, PhD will be leading the walk in Leicester, U.K. on Friday, May 17, 2019.
All registered awareness walkers will receive t-shirts, giveaways, and educational material while introducing the communities to the resources available. C.diff. infections are one of the leading healthcare-associated infections facing local communities.
Proceeds from the events will benefit the C Diff Foundation’s mission educating and advocating for C.difficile infection prevention, treatments, clinical trials, environmental safety, sepsis, and antibiotic awareness worldwide.
According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C.difficile), (formally known as Clostridium difficile) “has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone.”
Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.
We sincerely thank Vedanta Biosciences, Inc. for being the Diamond Sponsor of the 3rd Annual Global C.diff. Awareness 2K Walks. Vedanta Biosciences, Inc. is dedicated to finding treatments for patients with serious infections and immune diseases. Vedanta develops medicines made of consortia of bacterial strains which are selected to effect robust and durable changes in a patient’s gut microbiota. In contrast to fecal transplants or administration of fecal fractions, Vedanta’s medicines are pure, uniform compositions of bacteria manufactured from clonal cell banks, bypassing the need to rely on direct sourcing of fecal donor material of inconsistent composition. Vedanta is currently enrolling patients with recurrent C. difficile infections (CDI) in its CONSORTIUM study to evaluate VE303, an investigational treatment for CDI.
Our gratitude to all of the sponsors for their support and partnering with the C Diff Foundation in raising C. diff. awareness worldwide:
If you have any questions, please contact one of our staff members at
(727) – 205 – 3922 or e-mail: email@example.com
We look forward to walking with you on May 18th!
Follow Us On Twitter: #CdiffWalks2019